Loading
Abeona Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Alland Leila, was filed 20 May 2024.
Insider Decl.
283
Thresholds
n/a
Buy Volume
€1M
19 ops. · all time
Sell Volume
€9M
112 ops. · all time
Who traded when
BuySaleVazzano Joseph Walter13 sales
Vishwas Seshadri13 sales
Mark Alvino10 sales
O'Malley Brendan M.9 sales
Vasanthavada Madhav5 sales
Crombez Eric3 sales
+4 other insiders
Since the insiders bought
- +49.7%Entry US$4.31 · Close at T+365 US$6.45
- +58.5%Entry US$4.14 · Close at T+365 US$6.56
- +58.5%Entry US$4.14 · Close at T+365 US$6.56
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,338 of 26,280 companies
58.7
score / 100
Value67
Quality51
FCF yld-32%
Earn yld27%
EV/EBITDA3.7x
ROE-43%
Gross mgn41%
Net mgn·
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.60
Analyst consensus
8 analysts1.00/5
US$14.00Target US$18.88(+310%)US$30.00
Income statement
RevenueUS$5.8M
Gross profitUS$2.4M41% margin
EBITDAUS$78.6M1350% margin
Net incomeUS$71.2M-246.4% margin
Valuation
PER (trailing)7.8x
PER (forward)-22.2x
P/Book2.1x
Beta1.30
Balance sheet & cash
Market capUS$263M
Total debtUS$25M
Free Cash Flow-US$84.3M
Debt / Equity16%
Profitability & ownership
ROE-43.1%
ROA-24.6%
% insiders11.0%
% institutions75.1%
Last declaration on 29 September 2026
Declarations283 total
6,727 shares@ US$5.15560.012% mcap4.1% of flowCommon StockSEC144:0001972481-26-000286
4,902 shares@ US$5.15570.0085% mcap9.1% of flowCommon StockSEC144:0001972481-26-000287
9,191 shares@ US$5.15560.016% mcap3.3% of flowCommon StockSEC144:0001972481-26-000289
4,902 shares@ US$5.15560.0083% mcap10.0% of flowCommon StockSEC:0001493152-26-044971:0
6,727 shares@ US$5.15560.011% mcap4.2% of flowCommon StockSEC:0001493152-26-044972:0
19,608 shares@ US$5.15560.033% mcap2.9% of flowCommon StockSEC:0001493152-26-044974:0
9,191 shares@ US$5.15560.016% mcap3.4% of flowCommon StockSEC:0001493152-26-044973:0
15,000 shares@ US$5.86440.028% mcap9.2% of flowCommon StockSEC:0001493152-26-041068:0
1,478 shares@ US$6.530.0031% mcap0.7% of flowCommon StockSEC:0001493152-26-034246:0
12,050 shares@ US$6.96370.027% mcap10.6% of flowCommon StockSEC144:0001972481-26-000229
24,880 shares@ US$6.96370.056% mcap12.8% of flowCommon StockSEC144:0001972481-26-000230
12,606 shares@ US$6.96370.028% mcap38.6% of flowCommon StockSEC144:0001972481-26-000231
67,971 shares@ US$6.96370.15% mcap13.8% of flowCommon StockSEC144:0001972481-26-000232
12,606 shares@ US$6.96370.028% mcap38.6% of flowCommon StockSEC:0001493152-26-032740:0
12,050 shares@ US$6.96370.027% mcap10.6% of flowCommon StockSEC:0001493152-26-032742:0
67,971 shares@ US$6.96370.15% mcap13.8% of flowCommon StockSEC:0001493152-26-032744:0
24,880 shares@ US$6.96370.056% mcap12.8% of flowCommon StockSEC:0001493152-26-032746:0
102,180 shares@ US$6.2710.21% mcap47.3% of flowCommon StockSEC144:0001972481-26-000224
11,000 shares@ US$5.91712.4% of flowCommon StockSEC:0001493152-26-031906:0
222 sharesCommon StockSEC:0001493152-26-029092:0
18,160 shares@ US$5.71010.026% mcap7.6% of flowCommon StockSEC144:0001972481-26-000201
18,160 shares@ US$5.71017.0% of flowCommon StockSEC:0001493152-26-028777:0
25,646 shares@ US$5.39220.034% mcap10.1% of flowCommon StockSEC144:0001972481-26-000188
4,826 shares@ US$5.42952.8% of flowCommon StockSEC:0001493152-26-028019:0
25,646 shares@ US$5.39228.0% of flowCommon StockSEC:0001493152-26-028022:2
25 of 283 declarations
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc. is a US healthcare and pharma company listed on Nasdaq, with a market capitalisation of USD 263.0 million and 11% of its capital held by insiders. The largest purchases on file all belong to Stefano Buono, Director: EUR 450,700 on December 24, 2019, EUR 344,336 on April 11, 2019 and EUR 140,282 on April 10, 2019. Between April 25 and May 16, 2024, five insiders also bought, for EUR 142,948 in total.
On the selling side there are 112 sales worth EUR 9,404,115 (median EUR 45,716), against 19 purchases worth EUR 1,408,075 (median EUR 27,611), or 15% purchases among open-market trades. The largest sales are Todd Wider's, Director: EUR 619,228 on February 17, 2021 and EUR 497,344 on February 19, 2021, plus EUR 599,922 from SCO Capital Partners LLC on February 8. Brendan M. O'Malley, SVP, Chief Legal Officer, files the most, 35 out of 283, alongside 126 grants and 8 option exercises.
Read moreShow less
The pace has picked up: 64 filings in 2026 against 3 in 2016, and 66 over the last twelve months, of which 37 sales and no purchase. For the 19 purchases a 90-day result is stored: a median of --13.7%, with 47% of results positive (recorded past results, not a forecast).
